zimmer biomet new ceo focus restor inventori
physician relationship trust
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
valuat growth profit
methodolog valu compani
zimmer leader hip knee reconstruct enjoy fruit
wide econom moat addit smaller competitor
biomet zimmer undisput king hip knee implant
far expect favor demograph includ age
babi boomer rise obes fuel solid demand larg
joint replac off-set price declin unfortun
zimmer run near-term speed bump integr
issu suppli challeng qualiti concern attract
fda think take time work
turbul even though new manag place
histor zimmer benefit close relationship
orthoped surgeon make brand choic high switch
cost high-touch servic keep surgeon close tie
primari vendor surgeon bring enough profit
procedur keep hospit administr bay close
relationship vendor loyalti also explain market share
shift orthoped implant glacial best long zimmer
launch compar technolog within year rival
remain strong competit posit nevertheless
think surgeon influenc inevit erod practic
medicin chang respons healthcar reform long
term difficult surgeon run privat practic
profit open employ
think grow emphasi payer hospit
compar effect cost-effect make
condit tougher zimmer rival natur
orthoped innov tend evolutionari rather
revolutionari also less common orthoped innov
tap untreat patient pool unmet need
strategi cardiac devic maker pursu success
difficulti ethic issu surround random control
trial orthoped also weaken zimmer posit
press premium price think achiev meaning
innov orthoped implant challeng
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
zimmer biomet design manufactur market orthoped
reconstruct implant well suppli surgic equip
orthoped surgeri acquisit centerpuls biomet
zimmer hold lead share reconstruct market
unit state europ japan distribut sell product
hospit clinic world-wide brand name like nexgen zimmer
versi soplu pulsavac
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit
modestli rais fair valu estim
per share primarili reflect time valu money
secondarili slightli optimist project
oper leverag time frame despit
near-term turbul relat regulatori issu
manag chang think zimmer biomet wide
econom moat remain intact sourc moat
chang materi underli dynam
orthoped market remain balanc favor
manufactur follow acquisit biomet take
temper view combin firm prospect
work address short-term oper regulatori
issu project averag annual revenu growth
zimmer biomet trail orthoped
market growth mid-single-digit growth oper
incom taper low singl digit
would put profit slightli short
zimmer histor level
condit favor larg joint implant
volum patient feel financi stabl
enough undergo joint-replac procedur
project flat slightli growth knee hip
base case estim
averag annual volum growth knee hip
respect product line expect current
low-single-digit annual declin price continu
project smaller extrem surgic product spine
busi continu grow mid-single-digit clip
forc innov new product also
help zimmer fend price pressur pocket
assum zimmer cost equiti equival
rate return expect investor demand
averag sensit econom cycl rel
base averag volatil cash flow
extens orthoped product portfolio rate zimmer
uncertainti medium
bull case put zimmer valu per share
incorpor robust knee hip growth thank
better-than-expect volum gain smaller price
declin result growth match market
also assum averag annual growth extrem
trauma along mid-single-digit growth dental
surgic product zimmer abl resolv
oper regulatori issu bring consolid
oper margin back line past peak level
bearish scenario estim zimmer worth
per share scenario see less way
cost-sav synergi biomet declin
price almost complet off-set volum gain hip
knee trauma extrem dental surgic product
remain flat-to-declin zimmer oper
margin peak thank unfavor price
wholli off-set lower sale market
zimmer wide econom moat stem two major
sourc first substanti switch cost
orthoped surgeon extens instrument tool
set use prepar bone instal implant specif
compani learn curv becom profici
use one compani instrument signific
addit rel specialist orthoped
surgeon skill experi play outsiz role
clinic outcom patient issu leav
train master multipl
instrument system especi procedur volum
low maintain high surgic facil one
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
inventor file applic soon possibl inventor
also need provid detail applic order
head competitor may block improv patent
futur gener product new law also
mandat opposit review patent
grant result challeng patent
think firm like zimmer support extens legal
team better posit take advantag
new law file comprehens patent applic
timelin mount complex
patent grant
think anoth intang asset relationship
sale rep surgeon
medic devic equip orthoped sale rep play
critic role surgeon sale rep present
everi procedur teach surgeon use tool
kit prepar select instrument
right size sequenc procedur
orthoped surgeon may perform hip
replac knee replac year
sale rep provid valuabl servic small group
high-volum surgeon may perform five knee
replac day less need train
sale rep surgeon may wish hire nurs
handl procedur prepar
think zimmer moat trend remain stabl despit
near-term turbul due regulatori issu inventori
glitch new manag grasp rein think
surgeon favor zimmer biomet product
past like give firm leeway address
obstacl disrupt reliabl suppli
product brand histor fall behind key
orthoped competitor even year
necessarili perman impair underli busi
system surgeon prefer certain vendor
stretch back day resid train research
found surgeon stick prefer vendor
sale rep year use vendor
approxim orthoped procedur
time switch anoth instrument system
would requir take time train develop
relationship new sale rep work less effici
earli period master anoth vendor tool
possibl rais risk patient reduc
number procedur incom surgeon
dynam explain market share among six top
orthoped implant maker remain remark steadi
intellectu properti protect product portfolio
character evolutionari chang
technolog new gener product reli
intellectu properti establish earlier iter
devic follow chang patent law introduc
 switch first-inventor-to-fil
system previous first-to-inv system
think chang favor moat larger
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
recent competit activ around larg joint
replac driven indic expans
robot system includ total knee replac
mako robot smith nephew navio robot
reassur zimmer biomet acquisit rosa
robot firm pursuit total knee replac
indic put firm strong posit play
catch next month rosa robot give
zimmer biomet leg orthoped stalwart johnson
johnson reluct acquir type
although larger reimburs environ remain
tough expect on-going price pressur zimmer
biomet remain strong competit posit
combin compani access largest pool
surgeon train instrumentationestim
roughli total hip knee surgeon think
size combin surgeon pool along high
switch cost orthoped virtual guarante
zimmer nearli everi hospit vendor list
replac medicar
payer whittl away reimburs joint
reconstruct procedur demand expect
rise first babi boomer reach key age window
reimburs surgeon hip knee replac
procedur introduc bundl payment hip/kne
replac implant account
approxim half procedur reimburs
medicar zimmer find much difficult justifi
price increas reimburs remain pressur
erod reimburs also mean orthoped
procedur histor profit-cent
hospit less profit also suggest
orthoped surgeon could less influenc
hospit institut shift cardiovascular
neurosurgeri outsiz profit contribut
longer term zimmer histor relianc
surgeon relationship could serious weaken firm
econom moat triangul relationship among
physician hospit payer zimmer biomet
histor thrown lot surgeon make
brand choic histor posit
align zimmer surgeon typic free
agent could practic hospit long
orthoped surgeon brought profit procedur
hospit held sway relationship
hospit defer orthoped procedur
profit hospit
greater pressur manag profit hospit
administr assert bring cost
includ implant control
howev suggest orthoped surgeon
eager go along chang think
weaken surgeon influenc autonomi take
place gradual long time frame unlik primary-car
practition cardiologist repres
highest proport specialist sign
hospit healthcar system employe orthoped
surgeon repres last holdout privat practic
current orthoped surgeon salari
hospit system half still privat practic
long haul proport employe orthoped
surgeon undoubtedli grow gener
chang consid current rate convers
take year orthoped surgeon reach
level hospit employ cardiologist
alreadi reach meantim orthoped surgeon
remain highli independ enjoy autonomi
increas incom fee-for-servic framework resist
hospit effort limit brand choic mani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
attempt hospit made rein
analysi team formulari model -- mostli fail
face healthcar reform stake hospit
rais continu chip away
issu pilot account care organ
bundl reimburs grow
pressur orthoped surgeon
accommod
cost-contain measur could limit brand
choic medicar continu cut physician fee
joint replac orthoped surgeon may decid
better hospit employe would
acceler consolid brand choic hand
administr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth introduct gel-on zimmer single-inject
hyaluron acid product complement firm
broader rang knee implant orthoped
surgeon use gel-on treat mild
oth scarciti high-qual compar effect
research data make difficult orthoped
compani secur premium price time
payer hospit rais bar cost-
oorthoped surgeon often resist effort hospit
health system limit autonomi brand
choic one major factor contribut
consist failur program put forth
provid
ozimm amass impress portfolio
patent own control approxim
issu patent applic world-wide
oweak clinic data unfavor posit
formulari hinder
adopt gel-on
 could put pressur zimmer
continu shoulder consider cost high-
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
follow acquisit biomet firm
consist de-lever -- pay debt
billion end anticip substanti
de-lever decemb gross debt
stood billion roughli time trail
adjust ebitda expect zimmer biomet hit net
debt/adjust ebitda end year
estim manag seek lower gross
debt/ebitda time end think
goal may ambiti new manag could shift
base averag volatil cash flow
extens orthoped product portfolio rate zimmer
biomet uncertainti medium zimmer biomet
near-term risk bound regulatori infract
fda document number qualiti control
issu seriou perspect issu
resolv time manner product may
risk fda decid interven hold market
product pipelin candid regulatori review
relat regulatori challeng zimmer biomet also
need restor adequ inventori level order
sale rep effect appeal orthoped surgeon
greatest long-term strateg risk zimmer
manag team come grip chang
orthoped environ although chang unfold
slowli write wall bundl payment
surgeon join hospit employe
transpar price come pike
manag formul new model
orthoped product zimmer could left dust
meantim firm vulner product recal
relat legal fee inventori write-off
regulatori payer push devic registri
orthoped compani may subject frequent
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
discoveri product failur subsequ recal
zimmer could also see greater exposur consum
spend pattern increas cost-shar requir
push out-of-pocket expens onto individu patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
zimmer stewardship standard reflect former ceo
david dvorak tenur helm bryan hanson
step ceo role still earli assess
chang firm plan capit alloc
nonetheless fan hanson previou perform
covidien although delv
orthoped market past deep
understand competit dynam medic
technolog good handl hospit client
leadership skill ralli employe base
struggl cultur two legaci compani come
dvorak leadership zimmer biomet commit
acquir technolog execut number
tuck-in purchas substanti larger purchas
biomet isol event expect
scale acquisit regular basi firm
taken goodwil write-down provid us
measur reassur overpaid
merger acquisit seen hint
manag strateg vision partner close
orthoped surgeon intern innov
small acquisit technolog help practition
address wider span potenti treatment orthoped
patient think may relat david dvorak
tenur ceo began specul
dvorak legal background led stick larg
conserv decis zimmer firm gener
stuck knit focus develop larg joint
replac franchis result zimmer less
prepar take advantag faster growth trauma
extrem compar better
wors dvorak tenur heavili color
financi crisi fallout recess push
tradit reconstruct market slower-growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
zimmer biomet see anoth mis-step regulatori
wide-moat zimmer biomet run
speedbump anoth letter food
drug administr look specif
observ need address leav
fair valu estim unchang per share unlik
earlier fall recent one
highlight issu legaci zimmer manufactur
facil think natur latest observ
easili quickli address compar
issu rais legaci biomet facil
exacerb inventori issu zimmer biomet
alreadi deal
although neither impli immedi qualiti
problem like result implant failur
defect product regulatori issu biomet
plant substanti exceed typic qualiti process
data valid observ often character
suspect rectifi condit would
requir actual physic chang facil contrast
latest primarili focus inform
handl process legaci zimmer facil
exampl inconsist found process
document situat product conform
qualiti standard think type process-
procedure-focus matter rel easi address
expect zimmer biomet amelior situat
quickli said even zimmer biomet submit
remedi plan lightn speed ultim
resolut matter depend fda come
re-inspect last decemb firm submit
remedi plan fda address first
fall still wait undergo re-
think latest mis-step put pressur
new ceo bryan hanson clean thing get firm
back shape grow
zimmer biomet enjoy stabil fourth quarter
zimmer biomet report solid fourth-quart result
gener met expect leav fair
valu estim unchang point firm
manag stem declin implement plan address
regulatori suppli issu dog zimmer
biomet sinc late glitch yet put
bed continu weigh firm abil ramp
growth howev reassur new ceo bryan
hanson hear orthoped surgeon
train zimmer biomet product found
end user remain favor product
portfolio underscor confid zimmer wide
econom moat stem high switch cost
practition
full year zimmer deliv top-lin growth
constant currenc slightli better wed
project gross margin also better
expect howev special charg litig
biomet integr consult goodwil impair
ate earn plan hold steadi temper
project especi follow
hanson comment need comprehens
restor suppli product line-up evolut
dispar cultur follow acquisit biomet
thu far confid hanson identifi key
challeng need tackl howev understand
cultur slow chang expect zimmer biomet
continu trail market larg joint
would consid increas project
especi firm plan rectifi manufactur
execut defici begin yield result
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
like zimmer biomet pick ceo fve
pleas zimmer biomet new pick presid
ceo bryan hanson recent ran
minim invas therapi group
leav fair valu estim unchang
hanson new orthoped market balanc
think hell bring much-need new perspect
appetit tri differ idea wide-moat zimmer biomet
includ
significantli expand product
activ work address new target audienc hospit
cfo procur depart valu assess
committe zimmer biomet move much
conserv focus effort strengthen
relationship orthoped surgeon leadership
former ceo david dvorak think old med-tech
model sell sole practition enough
competit landscap inexor shift toward value-
hanson rise star covidien weve
impress abil focu mitg
busi penetr emerg market hanson
need tackl regulatori oper strateg
challeng new posit zimmer regulatori
front zimmer made progress remedi effort
 food drug administr work
time line covidien also dealt letter form
fda hanson tenur think
exposur come handi put zimmer qualiti issu
rest hope hanson oper
experi rectifi suppli issu dog
firm well challeng optim legaci
biomet zimmer work enhanc cross-sel
maintain relationship surgeon smoothli
shepherd sever divis tyco spun covidien
follow reorgan covidien divis
follow acquisit
think hanson potenti reshap zimmer biomet
strategi could biggest contribut long-term
health firm dvorak risk avers uncr
approach zimmer futur left firm two step
behind rival opinion introduct value-bas
reimburs open opportun forward-think
med-tech compani involv help
fortun high switch cost orthoped
surgeon help shield zimmer biomet
intens competit also buy time firm
readjust path
consid hanson hand help covidien climb
valu curv medic devic previou two year
involv wide-rang initi
take advantag value-bas reimburs think
hell bring fresh think zimmer
willing tri new initi would
surpris hanson push greater zimmer presenc
orthoped robot market exampl
zimmer biomet suffer anoth quarter anem
result wide moat remain intact
zimmer biomet post anem third-quart result
gener fell line temper expect
near term stand behind fair valu
firm wide moat rate quarterli revenu
constant currenc quarter highlight
oper chang may take time implement
third quarter last year number issu came
light concern state combin compani
inform technolog challeng shift suppli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
meet demand also third quarter
food drug administr rais number
concern legaci biomet plant warsaw
consid unusu seriou natur fda
observ anticip would take
month fulli remedi letter
resign former ceo david dvorak summer
on-going search new ceo lengthen
process fulli put regulatori issu bed return
manufactur facil full capac
despit soft perform larg joint segment
zimmer biomet fell behind market growth
larg joint volum rise mere price
declin basi point put quarterli hip knee
revenu neg territori stand stark contrast
rival quarterli volum gain knee
estim outstand execut mako robot
allow take full advantag zimmer
biomet current struggl howev wouldnt count
zimmer biomet race switch cost
practition remain high firm significantli larger
pool train surgeon buy firm time sort
issu interestingli estim saw quarterli
knee volum fall roughli interpret
favor sign strong zimmer wide moat remain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
